https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/les-medicaments-en-developpement/ 2022-06-16T02:06:09+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/03/Medicines-in-Development-scaled.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/explaining-public-reimbursement-delays-for-new-medicines-for-canadian-patients-8-5x11/ 2022-06-22T12:44:14+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2020/06/Early-Signs-of-Negative-Impacts-for-Patients-of-Health-Canada-Pharmaceutical-Pricing-Reforms.png https://innovativemedicines.bcdn.ca/resources/all-resources/how-would-a-single-payer-publicly-funded-national-pharmacare-program-affect-the-quality-of-access-to-medicines-for-canadian-patients-8-5x11/ 2022-06-22T12:45:09+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2020/07/CADTH-GapsInPublicPlans-8.5x11-EN-Final-pdf.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/early-signs-of-negative-impacts-for-patients-of-health-canada-pharmaceutical-pricing-reforms-8-5x11/ 2022-06-22T12:46:48+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2020/07/CADTH-EarlySigns-8.5x11-EN-Final-pdf.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/patient-access-to-new-medicines-in-canada-an-international-comparison-of-launch-and-public-reimbursement/ 2022-06-22T12:53:07+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2019/04/2019-CADTH-Poster-EN-1-pdf-scaled.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/time-to-listing-oncology-wait-times-for-public-reimbursement-of-cancer-medicines-need-to-improve/ 2022-06-22T13:00:03+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2018/06/TTL_Oncology_EN_Final_Page_1-scaled.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/time-to-listing-canadian-drug-review-and-public-reimbursement-process-an-overview/ 2022-06-22T13:02:49+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2018/06/TTL_Process_Overview_EN_Final-scaled.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/innovative-medicines-canada-members-economic-footprint-and-impact-in-canada/ 2022-06-22T13:05:12+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2017/11/EY-Key-Data-Infographic-EN_Page_1-scaled.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/public-drug-plans-then-and-now/ 2022-06-22T13:10:03+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/05/InnoMeds_BuyingDrugPlans_Web_2.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/our-industry-in-ontario/ 2022-06-22T13:12:59+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/09/Regional-Infographic-ON-EN.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/notre-industrie-en-ontario/ 2022-06-22T13:13:22+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/09/Regional-Infographic-ON-EN.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/listing-medicines-in-canada/ 2022-06-22T13:14:10+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/05/Listing-Medicines-in-Canada-EN.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/medicaments-inscrits-au-canada/ 2022-06-22T13:14:28+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/05/Listing-Medicines-in-Canada-EN.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/patient-safety-is-our-top-concern/ 2022-06-22T13:15:10+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/05/Patient-Safety-EN.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/la-securite-des-patients-est-au-coeur-de-nos-preoccupations/ 2022-06-22T13:15:28+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/05/Patient-Safety-EN.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/our-industry-in-saskatchewan/ 2022-06-22T13:16:28+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/09/InnoMeds_ProvincalFactSheet_Web_SK.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/notre-industrie-en-saskatchewan/ 2022-06-22T13:16:56+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/09/InnoMeds_ProvincalFactSheet_Web_SK_FR.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/our-industry-in-manitoba/ 2022-06-22T13:17:52+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/09/InnoMeds_ProvincalFactSheet_Web_MB.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/notre-industrie-au-manitoba/ 2022-06-22T13:18:19+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/09/InnoMeds_ProvincalFactSheet_Web_MB_FR.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/our-industry-in-british-columbia/ 2022-06-22T13:19:00+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/09/InnoMeds_ProvincalFactSheet_Web_BC.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/notre-industrie-en-colombie-britannique/ 2022-06-22T13:19:27+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/09/InnoMeds_ProvincalFactSheet_Web_BC_FR.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/our-industry-in-alberta/ 2022-06-22T13:20:16+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/09/InnoMeds_ProvincalFactSheet_Web_AB.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/notre-industrie-en-alberta/ 2022-06-22T13:20:43+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/09/InnoMeds_ProvincalFactSheet_Web_AB_FR.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/value-of-innovative-medicines/ 2022-06-22T13:21:34+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/09/InnoMeds_Values_Web_1-scaled.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/la-valeur-des-medicaments-novateurs/ 2022-06-22T13:22:47+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/09/InnoMeds_Values_Web_FR_1-scaled.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/value-for-canadas-knowledge-based-economy/ 2022-06-22T13:23:32+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/09/InnoMeds_Values_Web_4-scaled.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/la-valeur-pour-leconomie-du-savoir-canadienne/ 2022-06-22T13:24:21+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/09/InnoMeds_Values_Web_4-scaled.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/value-for-the-healthcare-system/ 2022-06-22T13:26:42+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/09/InnoMeds_Values_Web_FR_3-scaled.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/valeur-pour-le-systeme-de-soins-de-sante/ 2022-06-22T13:27:01+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/09/InnoMeds_Values_Web_FR_3-scaled.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/value-for-patients/ 2022-06-22T13:27:58+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/09/InnoMeds_Values_Web_2-scaled.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/la-valeur-pour-les-patients/ 2022-06-22T13:28:39+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/09/InnoMeds_Values_Web_FR_2-scaled.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/how-public-drug-plans-decide-to-buy-patented-medicines/ 2022-06-22T13:29:29+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/05/InnoMeds_BuyingDrugPlans_Web_1.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/regimes-publics-dassurance-medicaments-de-quelle-facon-les-regimes-publics-dassurance-medicaments-decident-dacheter-des-medicaments-brevetes/ 2022-06-22T13:31:04+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/05/InnoMeds_BuyingDrugPlans_Web_FR_2-1.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/intellectual-property-impact-timeline/ 2022-06-22T13:31:51+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/05/InnoMeds_CETATimeline_Web.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/calendrier-de-limpact-sur-la-propriete-intellectuelle/ 2022-06-22T13:32:38+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/05/InnoMeds_CETATimeline_Web.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/nombre-dessais-clinque-au-canada/ 2022-06-22T13:33:46+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/05/InnoMeds_ClinicalTrialsCA_Web_FR.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/les-essais-cliniques-contribuent-a-sauver-des-vies/ 2022-06-22T13:35:27+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/05/Clinical-Trials-Help-Save-Lives-FR.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/code-dethique-principles-directeurs/ 2022-06-22T13:36:51+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/05/InnoMeds_CodePrinciples_Web_FR.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/tendance-a-la-baisse-des-depenses-en-medicaments-brevetes-au-canada/ 2022-06-22T13:38:17+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/05/Downward-Spending-Trend-Patented-Medicines-FR-scaled.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/healthcare-spending-in-provinces/ 2022-06-22T13:39:03+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/05/Healthcare-Spending-in-Provinces-EN.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/les-depenses-de-sante-des-provinces/ 2022-06-22T13:39:41+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/05/Healthcare-Spending-in-Provinces-FR.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/medicines-in-development-by-the-numbers/ 2022-06-22T13:41:06+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/03/Medicines-in-Development-scaled.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/innovative-and-generic-medicines-whats-the-difference/ 2022-06-22T13:42:23+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/05/Innovative-and-Generic-Meds-EN.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/les-medicaments-novateurs-et-les-medicaments-generqiues-quelle-est-la-difference/ 2022-06-22T13:42:55+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/05/Innovative-and-Generic-Meds-FR.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/our-industry-in-new-brunswick/ 2022-06-22T13:43:36+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/05/InnoMeds_ProvincalFactSheet_Web_NB.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/notre-industrie-au-nouveau-brunswick/ 2022-06-22T13:44:07+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/05/InnoMeds_ProvincalFactSheet_Web_NB_FR.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/our-industry-in-newfoundland-labrador/ 2022-06-22T13:44:55+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/05/Regional-Infographic-NL-EN.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/notre-industrie-a-terre-neuve-et-labrador/ 2022-06-22T13:45:24+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/05/Regional-Infographic-NL-FR.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/our-industry-in-nova-scotia/ 2022-06-22T13:46:08+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/05/InnoMeds_ProvincalFactSheet_Web_NS.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/notre-industrie-en-nouvelle-ecosse/ 2022-06-22T13:46:44+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/05/InnoMeds_ProvincalFactSheet_Web_NS_FR.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/our-industry-in-prince-edward-island/ 2022-06-22T13:47:27+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/09/Regional-Infographic-PE-EN.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/notre-industrie-a-lile-du-prince-edouard/ 2022-06-22T13:47:58+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/09/Regional-Infographic-PE-FR.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/our-industry-in-quebec/ 2022-06-22T13:48:42+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/05/Regional-Infographic-QC-EN-1.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/notre-industrie-au-quebec/ 2022-06-22T13:49:11+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/05/Regional-Infographic-QC-FR-1.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/our-research-goes-beyond-our-walls/ 2022-06-22T13:50:12+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/05/Our-Research-Goes-Beyond-our-Wall-EN.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/nos-recherches-transcendent-nos-frontieres/ 2022-06-22T13:51:00+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/05/Our-Research-Goes-Beyond-Our-Walls-FR.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/les-regimes-dassurance-publics-canadiens-et-les-retards-dans-lacces-des-patients-aux-medicaments-novateurs/ 2022-06-22T13:52:16+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/05/20211201-public-insurance-plans-delays-EN.png https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/statistique-canada-le-secteur-de-la-recherche-et-du-developpement-pharmaceutique-2018/ 2022-06-22T13:52:40+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2021/11/2021-statscan-onepager-EN.png https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/verification-des-faits-sur-lindustrie-pharmaceutique/ 2022-06-22T13:53:06+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2021/06/20210601-PMPRB-industryfactcheck-e.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/les-depenses-de-sante-au-canada/ 2022-06-22T13:53:35+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/05/Healthcare-Spending-in-Provinces-FR.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/pourquoi-les-delais-de-remboursement-aux-nouveaux-medicaments-pour-les-patients-canadiens-dans-le-systeme-public-8-5x11/ 2022-06-22T13:55:16+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2020/06/Early-Signs-of-Negative-Impacts-for-Patients-of-Health-Canada-Pharmaceutical-Pricing-Reforms.png https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/comment-un-regime-national-dassurance-medicaments-a-payeur-unique-public-affectera-t-il-la-qualite-de-lacces-aux-medicaments-pour-les-patients-canadiens-8-5x11/ 2022-06-22T13:55:54+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2020/07/CADTH-GapsInPublicPlans-8.5x11-FR-Final-pdf.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/premiers-signes-dimpacts-negatifs-pour-les-patients-des-reformes-de-sante-canada-en-matiere-de-prix-des-produits-pharmaceutiques-8-5x11/ 2022-06-22T13:56:23+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2020/07/CADTH-EarlySigns-8.5x11-FR-Final-pdf.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/essais-cliniques-parraines-par-lindustrie/ 2022-06-22T13:56:52+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2019/07/Healthsystem-IHE-FR-Final-pdf.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/comparaison-entre-les-regimes-de-pi-pharmaceutiques-canadiens-et-internationaux/ 2022-06-22T13:57:55+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/06/CETA-International-Comparison-FR.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/les-regimes-publics-canadiens-couvrent-moins-de-nouveaux-medicaments-et-mettent-plus-de-temps-pour-les-approuver-relatif-a-la-plupart-des-pays-de-locde/ 2022-06-22T13:58:20+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2019/01/TTL_International_Comparison_FR-scaled.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/les-temps-dattente-pour-le-remboursement-des-medicaments-contre-le-cancer-dans-les-regimes-publics-doivent-sameliorer/ 2022-06-22T13:58:47+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2018/06/TTL_Oncology_FR_Final_web.png https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/le-processus-devaluation-et-de-remboursement-des-medicaments-dans-les-regimes-publics-au-canada-est-successif-et-chaque-etape-allonge-les-delais/ 2022-06-22T13:59:14+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2018/06/TTL_Overall_FR_Final_web.png https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/le-processus-devaluation-et-de-remboursement-des-medicaments-dans-les-regimes-publics-au-canada-un-apercu/ 2022-06-22T13:59:40+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2018/06/TTL_Process_Overview_FR_Final_web.png https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/le-cancer-pose-des-problemes-de-sante-uniques/ 2022-06-22T14:00:11+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2017/12/Oncology_Infographic_FR.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/innovative-medicines-economic-footprint-and-impact-in-canada/ 2022-06-22T14:00:36+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2017/11/EY-Key-Data-Infographic-FR_Page_1-scaled.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/chronologie-devenements-decouverte-de-medicaments/ 2022-06-22T14:02:28+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/05/Drug-Discovery-Timeline-FR.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/regimes-publics-dassurance-medicaments-alors-et-maintenant/ 2022-06-22T14:03:05+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/05/InnoMeds_BuyingDrugPlans_Web_FR_2-1.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/ethique-et-integrite-relations/ 2022-06-22T15:36:41+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/05/InnoMeds_Relationships_Web_FR.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/health-research-foundation/ 2022-06-22T15:37:27+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2015/06/Health-Research-Foundation-EN.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/la-fondation-pour-la-recherche-en-sante/ 2022-06-22T15:37:57+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2015/06/Health-Research-Foundation-FR.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/safety-of-vaccines/ 2022-06-22T15:38:39+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2015/06/Safety-of-Vaccines-EN.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/la-securite-des-vaccins/ 2022-06-22T15:39:38+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2015/06/Safety-of-Vaccines-EN.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/incremental-innovation/ 2022-06-22T15:40:13+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2015/06/Incremental-Innovation-EN-1.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/les-innovations-progressives/ 2022-06-22T15:40:29+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2015/06/Incremental-Innovation-EN-1.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/reflections-on-a-potential-pan-canadian-drug-formulary-medicines-industry-response-to-cadth-consultation/ 2022-06-23T14:47:03+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/04/CADTH_BIOTECanada.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/imc-diversity-equity-and-inclusion-framework-and-commitment-statement/ 2022-06-23T15:00:36+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2021/04/2021-DEI-onepager-image-EN.png https://innovativemedicines.bcdn.ca/resources/all-resources/imc-open-letter-on-diversity-equity-and-inclusion/ 2022-06-23T15:03:12+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2021/04/20210426_DEI-Open_Letter_FR_Final_Signed-pdf-1.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/2016-2019-analysis-of-private-drug-claim-cost-drivers/ 2022-06-23T15:28:13+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2021/01/2020-Cost-Driver-report-EN-pdf.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/2016-2019-analysis-of-private-drug-claim-cost-drivers/ 2022-06-23T15:28:38+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2021/01/2020-Cost-Driver-report-EN-pdf.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/making-canada-an-international-life-sciences-leader/ 2022-06-23T15:50:11+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2021/05/20210330_Making_Canada_International_Life_Sciences_Leader_FR_Final-pdf.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/canadian-consensus-framework-for-ethical-collaboration/ 2022-06-23T19:19:20+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/06/IMC_CONCENSUS_2016_HR_nobleed-pdf.jpeg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/canadian-consensus-framework-for-ethical-collaboration/ 2022-06-23T19:24:02+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/06/IMC_CONCENSUS_2016_FR_HR_nobleed-pdf.jpeg https://innovativemedicines.bcdn.ca/resources/all-resources/guidance-regarding-ethical-considerations-for-returning-to-in-person-interactions-with-healthcare-professionals-in-the-context-of-covid-19/ 2022-06-27T14:32:10+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2020/06/20200602_Ethical-considerations-for-interactions-with-HCPs-post-COVID-19-EN-pdf.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/guidance-regarding-ethical-considerations-for-returning-to-in-person-interactions-with-healthcare-professionals-in-the-context-of-covid-19/ 2022-06-27T14:33:21+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2020/06/20200602_Ethical-considerations-for-interactions-with-HCPs-post-COVID-19-FR-pdf.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/canadian-consensus-framework-statement-on-reinforcing-business-ethics-and-integrity-amidst-covid-19/ 2022-06-27T14:34:49+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2020/06/Canadian-Consensus-Framework-Statement-on-Reinforcing-Business-Ethics-and-Integrity-Amidst-COVID-19-pdf.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/note-for-guidance-on-virtual-interactions-with-healthcare-professionals/ 2022-06-27T14:36:31+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2021/09/Note-for-Guidance-Virtual-Interactions-with-HCPs-pdf.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/note-for-guidance-on-retaining-the-services-of-stakeholders/ 2022-06-27T14:37:55+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2019/11/Note_Guidance_Engagement_with_Stakeholders_EN_Final-pdf.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/note-for-guidance-on-retaining-the-services-of-stakeholders/ 2022-06-27T14:38:02+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2019/11/Note_Guidance_Engagement_with_Stakeholders_EN_Final-pdf.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/note-for-guidance-on-retaining-the-services-of-stakeholders/ 2022-06-27T14:38:18+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2019/11/Note_Guidance_Engagement_with_Stakeholders_EN_Final-pdf.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/note-for-guidance-on-retaining-the-services-of-stakeholders/ 2022-06-27T14:38:43+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2019/11/Note_Guidance_Engagement_with_Stakeholders_EN_Final-pdf.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/note-for-guidance-on-events-and-meetings-organized-or-sponsored-by-companies/ 2022-06-27T14:40:48+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2019/11/Note_Guidance_Organization_Sponsorship_Events_EN_Final-pdf.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/note-for-guidance-on-events-and-meetings-organized-or-sponsored-by-companies/ 2022-06-27T14:41:44+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2019/11/Note_Guidance_Organization_Sponsorship_Events_FR_Final-pdf.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/note-for-guidance-on-patient-support-programs-and-medical-practice-activities/ 2022-06-27T14:44:29+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2019/11/Note_Guidance_Patient_Support_Programs_PSP_EN_FInal-pdf.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/canadas-drug-review-and-public-reimbursement-process-is-sequential-and-every-step-adds-to-the-timeline/ 2022-06-28T19:24:50+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/06/TTL-Overall-EN-Final-pdf.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/canadas-drug-review-and-public-reimbursement-process-is-sequential-and-every-step-adds-to-the-timeline/ 2022-06-28T19:26:51+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2018/06/TTL-Overall-FR-Final-1.pdf https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/pcpa-overview-of-the-negotiation-process/ 2022-06-28T19:30:17+00:00 https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/pcpa-brand-practice-guidelines/ 2022-06-28T19:55:22+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2019/04/pcpa_brand_process_guidelines_fr-1.pdf https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/search-for-specific-brand-name-drug-negotiations-status-with-the-pcpa/ 2022-06-28T19:57:43+00:00 https://innovativemedicines.bcdn.ca/resources/all-resources/2016-2019-analysis-of-private-drug-claim-cost-drivers/ 2022-06-29T02:43:03+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2021/01/2020-Cost-Driver-report-EN-pdf.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/2016-2019-analysis-of-private-drug-claim-cost-drivers/ 2022-06-29T02:43:03+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2021/01/2020-Cost-Driver-report-EN-pdf.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/early-signs-of-negative-impacts-for-patients-of-health-canada-pharmaceutical-pricing-reforms/ 2022-06-29T14:41:25+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2020/06/20200630-CADTH-EarlySigns-FINAL-pdf-scaled.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/healthcare-spending-in-canada/ 2022-06-29T14:46:17+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/05/Healthcare-Spending-in-Provinces-EN.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/how-would-a-single-payer-publicly-funded-national-pharmacare-program-affect-the-quality-of-access-to-medicines-for-canadian-patients/ 2022-06-29T14:47:58+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2020/07/CADTH-GapsInPublicPlans-8.5x11-EN-Final-pdf.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/making-canada-an-international-life-sciences-leader/ 2022-06-29T14:52:36+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/06/20210330_Making_Canada_International_Life_Sciences_Leader_EN_Final-pdf.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/pcpa-brand-practice-guidelines/ 2022-06-29T14:57:56+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/06/pCPA_Brand_Process_Guidelines_EN_FINAL-s-pdf.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/pcpa-overview-of-the-negotiation-process/ 2022-06-29T15:01:48+00:00 https://innovativemedicines.bcdn.ca/resources/all-resources/search-for-specific-brand-name-drug-negotiations-status-with-the-pcpa/ 2022-06-29T15:04:18+00:00 https://innovativemedicines.bcdn.ca/resources/all-resources/industry-fact-check/ 2022-06-29T22:51:50+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2021/06/20210601-PMPRB-industryfactcheck-e.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/optimizing-patient-access-to-precision-therapies-preparing-for-the-emerging-era-of-advanced-testing/ 2022-06-30T14:45:45+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/06/20220212_Policy_Position_Optimizing_Patient_Access_Precision_Therapies_EN_Final-2-2.jpeg https://innovativemedicines.bcdn.ca/resources/all-resources/addendum-to-imc-submission-on-drugs-for-rare-diseases/ 2022-06-30T14:47:49+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/06/20210915_DRD_Follow_Up_Addendum_FINAL-1.jpeg https://innovativemedicines.bcdn.ca/resources/all-resources/letter-to-the-honourable-patty-hajdu/ 2022-06-30T14:52:40+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/06/20210504_Hon.-Patty-Hajdu_Correspondence-from-IMC-President-Pamela-Fralick_Redacted-1.jpeg https://innovativemedicines.bcdn.ca/resources/all-resources/2021-federal-pre-budget-consultation/ 2022-06-30T15:00:26+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/06/20210218_IMC_2021_Federal_Pre-Budget_Submission_EN_Final-1.jpeg https://innovativemedicines.bcdn.ca/resources/all-resources/2022-federal-pre-budget-consultation/ 2022-06-30T15:35:13+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/06/20210806_IMC_2021_pre-budget_submission_Final-1.jpeg https://innovativemedicines.bcdn.ca/resources/all-resources/house-of-commons-standing-committee-on-health-hesa/ 2022-06-30T15:48:34+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/06/20201106_HESA_Submission_Final-1.jpeg https://innovativemedicines.bcdn.ca/resources/all-resources/standing-committee-on-international-trade-ciit-study-of-canadas-international-trade-and-investment-policy/ 2022-06-30T15:52:27+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/06/20210430_CIIT_Brief_FINAL-1.jpeg https://innovativemedicines.bcdn.ca/resources/all-resources/imc-response-to-pmprb-draft-guidelines/ 2022-06-30T15:55:10+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/06/20200214_Innovative_Medicines_Canada_Guidelines_Response_FINAL-1.jpeg https://innovativemedicines.bcdn.ca/resources/all-resources/imc-and-btc-joint-response-to-cadths-transparency-consultation/ 2022-06-30T15:57:07+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/06/20200810_CADTH_Process_Consultation_IMC_BIOTECanada_Signed-1.jpeg https://innovativemedicines.bcdn.ca/resources/all-resources/research-note-oncology-clinical-trials-canada-within-the-international-context/ 2022-06-30T16:03:49+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/06/20211115_Research_Note_Oncology_CTs_CA_Int_EN_Final-1.jpeg https://innovativemedicines.bcdn.ca/resources/all-resources/imc-response-to-pmprb-2020-draft-guidelines/ 2022-06-30T16:07:27+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/06/2020804_IMC_PMPRB_2020_Guidelines_Submission_FINAL-1.jpeg https://innovativemedicines.bcdn.ca/resources/all-resources/importation-of-prescription-drugs-proposed-rule/ 2022-06-30T16:13:46+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/06/20200306_IMC-Importation-of-Prescription-Drugs-Proposed-Rule-_Docket-No.-FDA-2019-N-5711_Confidential-1.jpeg https://innovativemedicines.bcdn.ca/resources/all-resources/ised-consultation-on-biomanufacturing/ 2022-06-30T16:22:23+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/06/20210312_ISED_Biomanufacturing_IMC_response-1.jpeg https://innovativemedicines.bcdn.ca/resources/all-resources/pmprb-guidelines-notice-and-comment/ 2022-06-30T16:24:51+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/06/20210212_-IMC_Response_PMPRB_Guidelines_Notice_and_Comment-1.jpeg https://innovativemedicines.bcdn.ca/resources/all-resources/pmprb-notice-and-comment-response/ 2022-06-30T16:28:15+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/06/20210831_IMC_Response_PMPRB_Notice_and_Comment_response_August_2021-1.jpeg https://innovativemedicines.bcdn.ca/resources/all-resources/pre-budget-consultations-in-advance-of-the-upcoming-2021-federal-budget/ 2022-06-30T16:30:22+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/06/20200807_IMC_2021_Pre-Budget_Submission_Final-002-1.jpeg https://innovativemedicines.bcdn.ca/resources/all-resources/proposed-guidelines-monitoring-and-evaluation-plan/ 2022-06-30T16:35:42+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/06/20210621_IMC_Submission_GMEP_Consultation-EN-1.jpeg https://innovativemedicines.bcdn.ca/resources/all-resources/towards-a-value-based-and-pan-canadian-rare-disease-strategy/ 2022-06-30T16:37:45+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/06/20210326_IMC_Drug_Rare_Disease_Consultation_FINAL-1.jpeg https://innovativemedicines.bcdn.ca/resources/all-resources/the-canadian-research-and-development-pharmaceutical-sector/ 2022-06-30T16:40:00+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/06/20210507-statscan-EN-1.jpeg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/note-de-recherche-essais-cliniques-en-oncologie-la-position-du-canada-dans-le-contexte-international/ 2022-06-30T17:53:44+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2021/11/20211115_Research_Note_Oncology_CTs_CA_Int_FR_Final-1.jpeg https://innovativemedicines.bcdn.ca/resources/all-resources/bluesky-project/ 2022-06-30T19:22:17+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/04/Bluesky_Report-1-1.jpeg https://innovativemedicines.bcdn.ca/resources/all-resources/code-of-ethical-practices-guiding-principles/ 2022-06-30T19:46:32+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/05/InnoMeds_CodePrinciples_Web-scaled.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/2019-annual-report/ 2022-06-30T19:56:26+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/06/2019AnnualReviewEN-1.jpeg https://innovativemedicines.bcdn.ca/resources/all-resources/cost-drivers-analysis-of-private-drug-plans-in-canada-2016-2018/ 2022-06-30T20:01:49+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/06/Cost-Drivers-Analysis-Report_2019_withLinks-002-1.jpeg https://innovativemedicines.bcdn.ca/resources/all-resources/factors-influencing-delays-in-patient-access-to-new-medicines-in-canada-a-retrospective-study-of-reimbursement-processes-in-public-drug-plans-march-2019/ 2022-06-30T20:04:53+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/06/2019-delays-patient-access-1.jpeg https://innovativemedicines.bcdn.ca/resources/all-resources/pan-canadian-pharmaceutical-alliance-pcpa-timelines-analysis-and-policy-implications-february-2019/ 2022-06-30T20:07:43+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/06/2019-pcpa-timelines-analysis-1.jpeg https://innovativemedicines.bcdn.ca/resources/all-resources/ey-report-an-assessment-of-canadas-current-and-potential-future-attractiveness-as-a-launch-destination-for-innovative-medicines-january-2019/ 2022-06-30T20:09:50+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/06/2019_01_29_-IMC_PhRMA_LaunchSequencing_vFINAL3-1.jpeg https://innovativemedicines.bcdn.ca/resources/all-resources/2018-annual-report/ 2022-06-30T20:12:28+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/06/2018_IMC_Annual_Report_EN_PublicWeb_Final-1.jpeg https://innovativemedicines.bcdn.ca/resources/all-resources/2017-annual-report/ 2022-06-30T20:22:41+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/06/2017_Annual_Report_Public_Web_EN_Final-1.jpeg https://innovativemedicines.bcdn.ca/resources/all-resources/real-world-evidence-workshop-industry-input-imc-biotecanada-working-group-2018/ 2022-06-30T20:30:08+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/06/20181011_CAPT_RWE_Workshop_IMC_BTC_-Input_Final-1.jpeg https://innovativemedicines.bcdn.ca/resources/all-resources/guide-to-providing-clinician-input-and-feedback-with-the-pcodr-program-2018/ 2022-06-30T20:32:33+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/06/2018-11-pCODRClinicianInput_FeedbackGuide-1.jpeg https://innovativemedicines.bcdn.ca/resources/all-resources/value-demonstration-with-private-payers-adherence-to-treatment-employer-economic-impact-literature-review-2018/ 2022-06-30T20:35:40+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/06/2018_Octobre_Pre%CC%81sentation_VDI_PIVOT_Concerto-1.jpeg https://innovativemedicines.bcdn.ca/resources/all-resources/private-drug-plan-drug-cost-forecast-2017-2019/ 2022-06-30T20:37:49+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/06/20180174_IMC_AnnualReport_V19_FINAL-1.jpeg https://innovativemedicines.bcdn.ca/resources/all-resources/cost-drivers-analysis-of-private-drug-plans-in-canada-2012-2016/ 2022-06-30T20:40:58+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/06/20180809_Cost-Drivers-Analysis-Report_EN_Final-1.jpeg https://innovativemedicines.bcdn.ca/resources/all-resources/understanding-the-gap-a-pan-canadian-analysis-of-prescription-drug-insurance-coverage/ 2022-06-30T20:52:23+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/06/20170712-understanding-the-gap-1.jpeg https://innovativemedicines.bcdn.ca/resources/all-resources/data-analytics-and-members-economic-footprint-and-impact-in-canada/ 2022-06-30T20:58:38+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/06/20171030_EY-REPORT_IMC_FINAL-1.jpeg https://innovativemedicines.bcdn.ca/resources/all-resources/2016-annual-report/ 2022-06-30T20:58:54+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/06/2016_Annual-Report_Web_EN_Final-1.jpeg https://innovativemedicines.bcdn.ca/resources/all-resources/nanos-prescription-use-survey-summary/ 2022-06-30T20:59:30+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/06/2017-nanos-survey-1.jpeg https://innovativemedicines.bcdn.ca/resources/all-resources/private-drug-plan-drug-cost-forecast-2016-2018/ 2022-06-30T21:03:16+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/06/Private-Drug-Plan-Drug-Cost-Forecast-2016-2018-1.jpeg https://innovativemedicines.bcdn.ca/resources/all-resources/making-canada-better-2017-conference-summary-report/ 2022-06-30T21:05:33+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/06/Conference_Summary_MakingCanadaBetter2016_EN_Final-1.jpeg https://innovativemedicines.bcdn.ca/resources/all-resources/downward-trend-in-spending-on-patented-medicines-in-canada/ 2022-06-30T21:09:47+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/05/Downward-Spending-Trend-Patented-Medicines-EN-scaled.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/drug-discovery-timeline/ 2022-06-30T21:10:34+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/05/Drug-Discovery-Timeline-EN.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/ethics-and-integrity-relationships/ 2022-06-30T21:11:23+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2015/06/Ethics-and-Integrity-Relationships-EN-scaled.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/access-to-new-medicines-in-public-drug-plans-canada-and-comparable-countries-2016-annual-report/ 2022-06-30T21:22:56+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/06/20160524_Access_to_Medicines_Report_EN_Web-1.jpeg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/canadian-consensus-framework-statement-on-reinforcing-business-ethics-and-integrity-amidst-covid-19/ 2022-07-07T16:23:21+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2020/06/Canadian-Consensus-Framework-Statement-on-Reinforcing-Business-Ethics-and-Integrity-Amidst-COVID-19-pdf.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/comparison-of-canadian-and-non-canadian-pharmaceutical-ip-regimes/ 2022-08-16T19:07:03+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/06/CETA-International-Comparison-EN.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/cost-drivers-analysis-of-private-drug-plans-in-canada-2021/ 2022-08-23T14:11:42+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/06/2021-Cost-Drivers-report-EN-1.jpeg https://innovativemedicines.bcdn.ca/resources/all-resources/imc-response-to-pmprb-interim-approach-consultation/ 2022-08-26T14:30:25+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/07/20220718_PMPRB_July18_2022_Interim_Approach-002-pdf.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/developing-a-pan-canadian-genomics-strategy-innovative-medicines-canada-response/ 2022-08-26T14:31:00+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/07/20220624_ISED_Genomics_Consultation_Final-pdf.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/note-for-guidance-on-patient-support-programs-and-medical-practice-activities/ 2022-09-02T15:25:58+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2019/11/Note_Guidance_Patient_Support_Programs_PSP_EN_FInal-pdf.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/note-for-guidance-on-patient-support-programs-and-medical-practice-activities/ 2022-09-02T15:25:58+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2019/11/Note_Guidance_Patient_Support_Programs_PSP_EN_FInal-pdf.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/time-to-listing-canadas-drug-review-and-public-reimbursement-process-is-sequential-and-every-step-adds-to-the-timeline/ 2022-10-13T17:50:54+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2018/06/TTL_Overall_EN_Final_Page_1.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/2022-ontario-pre-budget-consultation/ 2022-10-14T17:47:51+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/01/2022_Ontario_Pre_Budget_Consultation1024_1.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/pre-budget-consultations-in-advance-of-the-2023-budget/ 2022-10-14T18:15:53+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/10/20221007_FINAL_PreBudget_Consultation1024_1-1.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/public-reimbursement-timelines-a-pandemic-snapshot/ 2022-11-07T19:41:36+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/11/20220930-CAPTL-TTL-Poster-V19-0021024_1.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/calendrier-des-remboursements-publics-un-apercu-de-la-pandemie/ 2022-11-08T16:23:10+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/11/20220930-CAPTL-TTL-Poster-FRV5pdf-0021024_1.png https://innovativemedicines.bcdn.ca/resources/all-resources/canadian-public-insurance-plans-and-delays-in-patient-access-to-innovative-medicines/ 2022-11-09T16:54:04+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/05/20211201-public-insurance-plans-delays-EN.png https://innovativemedicines.bcdn.ca/resources/all-resources/clinical-trials-in-canada-numbers/ 2022-11-09T16:56:12+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2016/05/6122_IMC_Number-of-Clinical-trials-graphic_v21024_1.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/explaining-public-reimbursement-delays-for-new-medicines-for-canadian-patients/ 2022-11-09T16:57:24+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2020/07/CADTH-TTL-8.5x11-EN-Final-pdf.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/time-to-listing-canadas-public-plans-cover-fewer-new-medicines-and-take-longer-than-most-oecd-countries-to-approve-them/ 2022-11-09T16:57:52+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2019/01/TTL_International_Comparison_EN-scaled.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/cancer-poses-unique-health-challenges/ 2022-11-09T16:58:11+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/05/Oncology_Infographic_EN.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/lettre-a-lhonorable-mona-fortier-c-p-deputee/ 2022-11-09T20:27:26+00:00 https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/lettre-a-lhonorable-jean-yves-duclos-c-p-depute/ 2022-11-09T20:35:36+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/11/20221108_Lettre_Ministre_Duclos-pdf.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/lettre-a-lhonorable-francois-philippe-champagne-c-p-depute/ 2022-11-09T20:38:33+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/11/20221108_Lettre_Ministre_Champagne-1.pdf https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/lettre-a-lhonorable-dominic-leblanc-c-p-depute/ 2022-11-09T20:45:28+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/11/20221108_Lettre_Ministre_Leblanc-pdf.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/ministerial-pmprb-guideline-letter-to-the-hon-francois-philippe-champagne-p-c-m-p/ 2022-11-09T20:45:58+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/11/20221108_LTR_Minister_Champagne-pdf.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/letter-to-the-honourable-mary-ng-p-c-m-p/ 2022-11-09T20:46:03+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/11/20221108_LTR_Minister_Ng-pdf.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/letter-to-the-hon-chrystia-freeland-p-c-m-p/ 2022-11-09T20:46:11+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/11/20221108_LTR_Minister_Freeland-pdf.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/letter-to-the-honourable-jean-yves-duclos-p-c-m-p/ 2022-11-09T20:46:18+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/11/20221108_LTR_Minister_Duclos-pdf.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/canadian-drug-access-pathway/ 2022-11-10T17:46:20+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/11/6132_IMC_Drug-Cost-Process-Map_update_Nov2022_v9-1.pdf https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/cadre-accords-novateurs/ 2022-11-17T16:17:44+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/11/IAFramework-FR-2022-V1withLinks.pdf https://innovativemedicines.bcdn.ca/resources/all-resources/innovative-agreements-framework/ 2022-11-18T21:14:37+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/11/IAFramework-2022-V2withLinks_Page_01.png https://innovativemedicines.bcdn.ca/resources/all-resources/cost-drivers-analysis-of-private-drug-plans-in-canada-2022/ 2022-11-25T21:30:09+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/11/2022CostDriversReporFINwithLinks_Page_01-scaled.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/analyse-des-generateurs-de-couts-2022/ 2022-12-07T16:10:47+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/11/2022CostDriversReportFR-V7ba.pdf https://innovativemedicines.bcdn.ca/resources/all-resources/2022-code-of-ethical-practices/ 2022-12-16T19:46:57+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/01/2022-Code-of-Ethical-Practices-EN-Final_Page_001.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/code-dethique-2022/ 2022-12-16T19:53:46+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/01/2022-Code-of-Ethical-Practices-FR-final-pdf.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/suspension-reformulation-pmprb-guidelines-urgently-required-imc-response-pmprb-2022-guidelines-proposals/ 2023-01-06T19:37:22+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/12/202211205_IMC_PMPRB_2022_Guidelines_Consultational_final_Page_1.png https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/voie-dacces-pour-les-medicaments-au-canada/ 2023-01-12T14:10:55+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2022/11/6132-MNC-Voie-acces-medicaments-canada-nov2022-v5.png https://innovativemedicines.bcdn.ca/resources/all-resources/alberta-budget-submission-2023/ 2023-02-15T18:01:12+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2023/02/Screenshot-2023-02-15-at-12.58.53.png https://innovativemedicines.bcdn.ca/resources/all-resources/increasing-access-to-innovative-medicines-lets-talk-budget-2023/ 2023-02-15T18:07:36+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2023/02/6297_IMC_Department_Pre-Budget_2023_v3-pdf.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/ontario-prebudget-submission/ 2023-03-08T14:53:17+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2023/03/20230125_Ontario_PreBudget_Submission-pdf.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/standing-committee-on-public-accounts/ 2023-03-15T15:23:35+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2023/03/20230314_Letter_Standing_Committee_on_Public_Accounts-pdf.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/innovative-access-arrangements-and-managed-entry/ 2023-04-04T19:24:10+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2023/04/6328_IMC_ME_IAA_Report_v6-pdf-1.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/dispositions-novatrices-en-matiere-dacces-et-accords-de-gestion-du-lancemen/ 2023-04-05T16:21:54+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2023/04/6328_IMC_ME_IAA_Report_French_v2-003-pdf.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/letter-to-health-canada-regarding-the-draft-guidance-on-advanced-therapeutic-products-framework/ 2023-05-04T20:10:54+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2023/05/20230313_IMC_response_ATP_draft_guidance_document_Final-pdf.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/letter-to-health-canada-regarding-the-proposed-plan-for-the-future-use-and-availability-of-the-drug-establishment-licence-del-and-good-manufacturing-practices-gmp/ 2023-05-04T20:11:02+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2023/05/20230411_IMC_letter_DEL_GMP_Consultation-pdf.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/letter-to-health-canada-regarding-the-regulations-amending-certain-regulations-made-under-the-food-and-drugs-act-agile-licensing/ 2023-05-04T20:11:09+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2023/05/20230426_IMC_Comments_Agile_Licensing_Regs_Final-pdf.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/clinical-trials-in-canada/ 2023-05-04T20:27:41+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2023/05/6354_IMC_ResearchNote_ClinicalTrialsCanada_2023_v2-pdf.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/letter-to-dr-melanie-bourassa-forcier-acting-chairperson-patented-medicine-prices-review-board-pmprb/ 2023-05-05T15:56:09+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2023/05/20221128_LTR_Dr.-Melanie-Bourassa-Forcier_PMPRB-pdf.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/dr-melanie-bourassa-forcier-interim-chair-patented-medicine-prices-review-board-pmprb/ 2023-05-05T20:56:23+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2023/05/20221118_LTR_Dr.-Melanie-Bourassa-Forcier_PMPRB-pdf.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/lettre-a-dre-melanie-bourassa-forcier-presidente-par-interim-conseil-dexamen-du-prix-des-medicaments-brevetes-cepmb/ 2023-05-05T20:59:06+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2023/05/20221128_LTR_Dr.-Melanie-Bourassa-Forcier_PMPRB-fr_ca-pdf.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/lettre-a-dre-melanie-bourassa-forcier-presidente-par-interim-conseil-dexamen-du-prix-des-medicaments-brevetes-cepmb-2/ 2023-05-05T21:00:49+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2023/05/20221118_LTR_Dr.-Melanie-Bourassa-Forcier_PMPRB-fr_ca-pdf.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/elaboration-dune-approche-canadienne-de-gestion-du-lancement-pour-les-nouvelles-innovations-que-peut-apprendre-le-canada-de-leurope/ 2023-05-16T15:46:41+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2023/05/999999999.20230516145525310.999999999.20230516145525310Os8LH.jpeg https://innovativemedicines.bcdn.ca/resources/all-resources/submission-for-the-parliamentary-consultations-on-bill-15-an-act-to-make-the-health-and-social-services-more-effective/ 2023-06-08T16:45:14+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2023/06/6377_IMC_QOT-Bill15-Submission_eng_v3-pdf.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/soumission-pour-les-consultations-parlementaires-sur-le-projet-de-loi-15-loi-visant-a-rendre-le-systeme-de-sante-et-de-services-sociaux-plus-efficace/ 2023-06-08T16:46:02+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2023/06/6377_IMC_QOT-Bill15-Submission_fre_v1-pdf.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/addendum-to-innovative-medicines-canada-submission-on-national-pharmacare/ 2023-06-08T17:48:45+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2023/06/20230601-Addendum-to-Innovative-Medicines-Canada-Submission-on-National-Pharmacare_FINAL-pdf.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/submission-to-advisory-council-on-the-implementation-of-national-pharmacare/ 2023-06-08T17:50:11+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2023/06/20180928_IMC_Submission_to_Advisory_Council_on_National_Pharmacare_Final_Combined_EN-pdf.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/submission-for-the-annual-regulatory-modernization-bill/ 2023-06-22T14:08:06+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2023/06/20230612_Annual_Regulatory_Modernization_Bill_IMC_Submission_Final-pdf.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/consultation-on-competition-policy-submission-of-imc/ 2023-07-10T17:54:54+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2023/07/Consultation-on-Competition-Policy-Submission-of-IMC-pdf.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/comments-on-the-public-health-agency-of-canadas-pandemic-instrument-partner-and-stakeholder-engagement-forum/ 2023-07-10T17:55:07+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2023/07/Pandemic-Instrument-Engagement-Forum_IMC-Submission-pdf.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/pcpa-temporary-access-process-innovative-medicines-industry-consultation-response/ 2023-08-21T18:57:46+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2023/08/20230818_IMC_BIOTECanada_pTAP_response-pdf.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/imc-response-to-the-pmprbs-2023-interim-guidance-consultation/ 2023-08-21T19:00:23+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2023/08/20230821_IMC_PMPRB_2023_Interim_Approach_Consultation_Final-pdf.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/cost-of-a-private-drug-plan-claim/ 2023-09-15T16:02:04+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2023/09/cost-of-claims-report-cover.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/la-valeur-des-medicaments-au-canada/ 2023-10-05T14:02:04+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2023/09/6456_IMC_ValueofMedicines_EFPIA_casestudies_2023_v2-fr_ca-pdf.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/two-years-is-too-long-understanding-canadas-drug-access-pathway/ 2023-10-11T17:15:25+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2023/10/imc-screen-grab.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/prix-galien-canada-product-innovation-guidelines/ 2023-11-14T20:57:31+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2023/04/2023-Prix-Galien-Canada-Innovative-Product-Award-Guidelines-1.jpeg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/lignes-directrices-sur-le-prix-galien-canada-produit-innovateur/ 2023-11-14T20:59:49+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2023/05/20230412_Prix_Galien_Product_Award_Guidelines_FR-pdf.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/formulaire-de-candidature-pour-le-prix-galien-canada-produit-innovateur/ 2023-11-15T18:55:45+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2023/04/2023-Prix-Galien-Innovative-Product-Award-Submission-Form-Instructions-FR-1.jpeg https://innovativemedicines.bcdn.ca/resources/all-resources/cost-drivers-report-2023/ 2023-12-04T20:06:24+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2023/10/CostDriver2023_ENG_v20-pdf.jpg https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/analyse-des-generateurs-de-couts-2023/ 2023-12-04T20:12:05+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2023/10/CostDriver2023_FRE_v20.png https://innovativemedicines.bcdn.ca/resources/all-resources/imc-response-to-the-pmprbs-2023-scoping-paper-for-the-consultations-on-the-boards-guidelines/ 2024-01-04T22:23:58+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2024/01/20231220_IMC_PMPRB_2023_Guidelines_Scoping_Response.png https://innovativemedicines.bcdn.ca/fr/ressources/toutes-les-ressources/le-secteur-de-la-recherche-et-du-developpement-pharmaceutique-2020/ 2024-01-15T12:23:03+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2024/01/Stats-Can_FRE-1.jpeg https://innovativemedicines.bcdn.ca/resources/all-resources/prix-galien-canada-product-innovation-award-submission-form/ 2024-07-05T20:05:47+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2023/04/2023-Prix-Galien-Innovative-Product-Award-Submission-Form_Instructions-EN-1.jpeg https://innovativemedicines.bcdn.ca/resources/all-resources/the-canadian-research-development-pharmaceutical-sector-2020/ 2024-07-05T20:06:05+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2024/01/Stats-Can_ENG-1.jpeg https://innovativemedicines.bcdn.ca/resources/all-resources/value-of-medicines-in-canada/ 2024-07-05T20:06:16+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2023/09/6456_IMC_ValueofMedicines_EFPIA_casestudies_2023_v2-pdf.jpg https://innovativemedicines.bcdn.ca/resources/all-resources/developing-a-canadian-managed-entry-approach-for-new-innovation-what-can-canada-learn-from-europe/ 2024-07-05T20:06:32+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2023/05/999999999.20230516145525310.999999999.20230516145525310Os8LH.jpeg https://innovativemedicines.bcdn.ca/resources/all-resources/testing/ 2026-06-29T18:39:19+00:00 https://innovativemedicines.bcdn.ca/wp-content/uploads/2024/07/2S3WFdt8SqU-HD.jpg